915095-85-1

Basic information

• Product Name: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone
• Synonyms: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone;Methanone, [5-Bromo-2-Chloro-phenyl](4-Fluoro Phenyl);Bromo fuloro benzone
• CAS NO: 915095-85-1
• Molecular Formula: C₁₃H₇BrClFO
• Molecular Weight: 313.5494832
• EINECS: -0
• Mol File: 915095-85-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 390.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.568±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(915095-85-1)
• EPA Substance Registry System: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(915095-85-1)

Safety Data

• Hazardous Substances Data: 915095-85-1(Hazardous Substances Data)

Usage

General Description

(5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone, also known as Bromofluorophenylmethylketone, is a chemical compound consisting of a bromo-chloro-substituted phenyl ring attached to a fluorophenyl group via a methanone functional group. It is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone has been studied for its potential biological activities, including its antibacterial and antifungal properties. It is important to handle this compound with care and follow proper safety protocols due to its potential hazardous properties.

Upstream product

• 462-06-6 fluorobenzene 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 403-43-0 4-fluorobenzoyl chloride 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 

Downstream Products

• 915095-89-5 (S)-4-bromo-1-chloro-2-(4-tetrahydrofuran-3-yloxy-benzyl)benzene 
• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 864070-44-0 empagliflozin 

Relevant articles and documents

Preparation method of polysubstituted diphenyl ketone

The preparation method comprises the following steps: (1) a compound represented by the formula II and a compound shown III as a raw material; and synthesizing the compound as shown IV. (2) The compound of Formula IV is subjected to Fries rearrangement to produce a compound of Formula V. (3) A compound of Formula V is subjected to a halogenation reaction in contact with a halogenation reagent to prepare a multi-substituted diphenyl ketone represented by Formula I. Wherein, X is selected from H, F, Cl, Br, I. R1 Selected H from F Cl, Br I are RO selected R from H, C1 - C6. X is selected from F, Cl, Br, and i. The present invention is capable of improving the yield and selectivity of the target product.

Synthetic method of empagliflozin

The invention provides a brand-new synthesis process of empagliflozin. According to the process, a boric acid ester is used for halogen removal, and specific reaction conditions are combined, so thatempagliflozin can be prepared with high yield and simplicity and convenience in operation. The synthesis method of empagliflozin has the advantages of mild reaction conditions, high total yield, few side reactions and convenience in operation, thereby being beneficial to industrial production and cost control.

A NEW HETEROCYCLIC COMPOUND: CRYSTAL STRUCTURE AND ANTICANCER ACTIVITY AGAINST HUMAN LUNG ADENOCARCINOMA CELLS

Abstract: New heterocyclic compound (S)-3-(4-(5-bromo-2-chlorobenzyl)phenoxy)tetrahydrofuran (1), designed by utilizing 5-bromo-2-chlorobenzoic acid (2) as the starting material, is obtained by the organic synthesis and then characterized by single crystal X-ray crystallography, 1H NMR and IR spectroscopy. In the biological study, the CCK-8 assay is performed to evaluate the inhibitory effect of the compound on SPC-A-1 human lung adenocarcinoma cells in vitro by measuring the cancer cell viability. Then, the anticancer activity of the compound is also confirmed by the in vivo xenograft experiment by measuring the mice body weight and the cancer volume.